Awards and Honors, Free News Articles, NonProfit and Charities, Regional Events

November Is C. difficile Awareness Month With An Annual Conference, Recognizing Subject Matter Experts, Expressing Gratitude to US Governors

TAMPA, Fla. -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues: 100% Live-online presentations.

The Conference registration was complimentary this year. To learn more about this extraordinary conference, guest speakers, and the diverse topics presented visit: https://www.cdiff2021.com

For conference coverage visit ContagionLive Infectious Diseases Today: https://www.contagionlive.com/latest-conference

On behalf of the C Diff Foundation, Sahil Khanna, M.B.B.S, M.S. proudly presented the Lifetime Achievement Award to Dale Gerding, MD, MACP, FIDSA, FSHEA for his outstanding vision, dedication, and commitment and for the advancement of Clostridioides difficile research, development, and care through the years. The Dale Gerding Lifetime Achievement award will be presented annually during the C Diff Foundation's November conference to a healthcare professional meeting the criteria, nominated by peers, and awarded by Dr. Gerding himself.

The C Diff Foundation "Making a Difference: Innovations in Infection Prevention" 2021 award was presented to PhoneSoap acknowledging their exceptional organization who is making a difference in the Infection Prevention community, with their innovative products, services, and technologies.

The award was accepted by Wes LaPorte, CEO of PhoneSoap. "PhoneSoap's mission has always been to limit the spread of infectious diseases through science and technology. We are honored to accept the Innovations in Infection Prevention award of 2021 from the C Diff Foundation given their very important endeavor to bring awareness, education, and advocacy globally," stated LaPorte.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine).

Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to all the Sponsors and Keynote speakers for their generous support of the 9th Annual International C. diff. Conference and Health EXPO. Together we deliver superior educational up-to-date data, advance the healthcare professional knowledge and understanding of the topics discussed, and serve as the leading organization educating and advocating for C. difficile infection prevention, treatments, clinical trial, diagnostics, support, and environmental safety worldwide. We are grateful to be the leading resource for patients, families, caregivers, and healthcare professionals.

Many US Governors have signed a state proclamation proclaiming November 2021 as Clostridioides difficile (C. difficile, C. diff.) Infection Awareness Month.

"Our shared goal is to witness a significant increase in C. difficile awareness, with a noted reduction in C. difficile infections worldwide by the year 2025. We would also like to thank Seres Therapeutics, Rebiotix, a Ferring Company, and Ferring Pharmaceuticals for their efforts and support with this endeavor," stated Nancy C. Caralla, Executive Director of the C Diff Foundation.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiff2021 #cdiffawarenessmonth

C Diff Foundation(TM) is a trademark of C Diff Foundation, established 2012 in the U.S.

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Free News Articles, NonProfit and Charities, Regional Events

9th Annual C. diff. Conference and Health EXPO Pushes Past COVID-19 and Embraces Virtual Technology to Provide Global Online Learning for Healthcare Professionals on Nov. 4-5

TAMPA, Fla. -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO is honored to welcome over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. World-renowned presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues from 10 a.m. - 4 p.m. ET on Nov. 4 - 5, 2021: 100% Live-online presentations, on-demand poster presentations, exhibitors, and real-time networking opportunities available. Conference registration is complimentary this year.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit https://www.cdiff2021.com.

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

"The annual C Diff Foundation conference is a highlight of my learning year. The combination of academia, pharmaceutical, and governmental representation creates a learning environment that is second to none. I went initially in 2014 and have circled the conference dates on my calendar annually as immobile. The timing during C. difficile awareness month is tremendous as it summarizes all of the newest findings throughout the year," stated Paul Feuerstadt, MD, FACG, AGAF.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community.

C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine). Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia, and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

Their gratitude is also extended to Ferring Pharmaceuticals for being the Platinum Sponsor of the 9th Annual International C. diff. Conference and Health EXPO. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information, please visit https://www.ferringusa.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation on Twitter @cdiffFoundation #cdiff2021 #cdiffawarenessmonth

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities, Regional Events

COVID Variants Do Not Stop C. diff. Awareness Walks Worldwide

TEANECK, N.J. -- C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT. Learn more at: https://www.cdiffwalks.com

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus and the variants of SARS-CoV-2 that have been emerging and circulating around the world throughout the COVID-19 pandemic.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"C Diff Foundation volunteering members have a passion to improve the lives of patients, families, and caregivers who have been impacted by C. diff. infections worldwide," says Nancy C. Caralla, Founding President, Executive Director of the C Diff Foundation. "At the in-person C. diff. Awareness Walks, a safe distance will be maintained, and hand sanitizer will be available to ensure a safe outdoor event. 'Let's Walk' presents educational information shared by health care professionals, and C. diff. Survivors, through on-demand walks and livestream options located on the dedicated event website: https://cdiffwalks.com."

Thank you, Ferring Pharmaceuticals, for being the Global Sponsor of the 5th Annual Global C. diff. Awareness Walks. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information visit https://www.ferringusa.com.

We also extend our thanks to Seres Therapeutics, Inc. for being the Diamond Sponsor of the 5th Annual Global C. diff. Awareness Walks.

Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiffwalks2021 #cdiff2021

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

MEDIA CONTACT:

Kathy Bischoff, Global Walk Committee

kathy@cdifffoundation.org

(727) 205-3922

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0920s2p-cdf-events-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, NonProfit and Charities

Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness

TAMPA, Fla. -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences. The patients, family members, and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, and educators who are helping to change the way individuals maneuver through a C. difficile infection, worldwide.

Unlike other presentations on this topic, C. diff. Survivors will share their C. diff. infection journeys to provide a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials, and studies, C diff. in pediatric patients and more.

To register for this global live-online event, visit: https://cdifffoundation.org/patient-family-caregiver-symposium-july-16-2021/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

It reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation #cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation(TM) is a trademark of the C Diff Foundation, established 2012 in the U.S.

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Books and Publishing, Business, Free News Articles, Product Launches

A three-time C. diff. Survivor and Registered Dietician publish book for patients, families, and caregivers impacted by Clostridioides difficile

TAMPA, Fla. -- In the new book, "Managing a C. difficile Infection: For Patients, Families, and Caregivers" (ISBN: 979-8519789851), Nancy C. Caralla, three-time C. diff. Survivor, Founding President, Executive Director of the C Diff Foundation, and Karen F. Factor, MS, RD. LDN, Nutrition Wellness Chairperson of the C Diff Foundation share their knowledge and experience with patients, family members, and caregivers who have been impacted by a C. difficile infection (CDI) and CDI recurrences.

The book will answer the many questions focused on C. difficile infections, C. difficile prevention, home environment cleaning, nutrition, while introducing the readers to the microbiome and clinical trials.

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About the Authors

Nancy C Caralla, Founding President, and Executive Director of the C Diff Foundation is a three-time Clostridioides difficile infection (C. diff., C. difficile) survivor. She has accumulated over 25 years of experience in the nursing profession blended with over 25 years of experience in international construction management. Over the past several years, Nancy, in partnership with the C Diff Foundation members, focuses on raising C. difficile awareness through education and advocating for Clostridioides difficile infection prevention, treatments, clinical trials, and environmental safety worldwide.

Karen F. Factor, Registered Dietitian (RD), C Diff Foundation's Chairperson of the Nutrition and Wellness Committee, is uniquely trained in the science of nutrition and practice of dietetics to design and provide medical nutrition therapy (MNT) and other evidence-based applications of the Nutrition Care Process (NCP) that exemplify the profession's systematic approach to providing high-quality nutrition care to individuals experiencing dietary challenges, especially during a CDI.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission educating and advocating for C. diff. infection (CDI) prevention, treatments, clinical trials, environmental safety, and support. The C Diff Foundation(tm) is the leading global patient advocacy organization.

Their mission continues moving forward and growing through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

MULTIMEDIA:

*PHOTO Link for media: https://www.Send2Press.com/300dpi/21-0628s2p-cdiff-book-300dpi.jpg

*Caption: Cover, "Managing a C. difficile Infection: For Patients, Families, and Caregivers" (ISBN: 979-8519789851).

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities, Product Launches, Software

C Diff Foundation Releases ‘C diff and You’ App for Patients, Families, and Caregivers

TAMPA, Fla. -- C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

The free app, "C diff and You," is available on the Apple Store and Google Play, and was designed by the C Diff Foundation as an interactive educational tool allowing users to access easy-to-understand information about C. diff. infection prevention, treatments, clinical trials, support, nutrition, diagnostics, and environmental safety.

Clostridioides difficile infection, also called C. diff., CDI, C. difficile, or CDAD, is a life-threatening infection.

"I am really pleased to see this further addition to the C Diff Foundation's catalogue of achievements. This is an ideal way to communicate information far and wide," stated Professor Mark Wilcox, MD, FRCPath.

"There are patients, families, and caregivers isolated, and experiencing social-economic changes resulting from the COVID-19 pandemic. In the Global efforts to slow the spread of the COVID-19 virus the ramifications being witnessed range from loss of wages to difficulties meeting housing, utilities, nutrition, and healthcare expenses down to basic cable and internet connections. The one common denominator remaining accessible is the Mobile (also called Cell) phone. Developing the mobile application, 'C diff and You,' places the C. diff. community in the palm of their hands continuing to support the patients, families, and caregivers who desperately need to know that they are not alone no matter where they are," says Nancy C. Caralla, Founding President, and Executive Director of the C Diff Foundation.

Through the deployment of this app, the C Diff Foundation continues with its commitment to evolve resources to unite patients, families, and healthcare providers in the fight against C. diff. infections. The app focuses on quality resources directly relevant to patients and their care providers, aiming to lower the anxiety and fear associated with a CDI and provide easy access to reliable information to all users. "C diff and You" will also provide users with direct access to patient-centered care information, educational episodes of the "C. diff. Spores and More" archived radio episodes, and the C. diff. Global Tele-Support Network with a one tap key to "Sign Up Today" for Caregiver, Nutrition, and Physician support sessions. The telephone access key connects the app user directly to the C Diff Foundation office and the Foundation's Triage Nurses.

"Patients with a C. difficile infection are in desperate need for education on the risk factors for the infection, how to stop infection spread, the chances of recurrence, and treatment options for recurrent C. difficile. The 'C diff and You' app is an outstanding and user-friendly platform for patients to get accurate information on C. difficile infection and has resources that patients can use," says Sahil Khanna, M.B.B.S., M.S.

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation
#cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation™ is a trademark of The C Diff Foundation, established 2012 in the U.S.

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, General Editorial, NonProfit and Charities

C Diff Foundation Hosts Live-Online Symposium for Patients, Families and Caregivers

TAMPA, Fla. -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, educators and patients who are transforming the patient experience, and changing the way people experience C. diff. infections, worldwide.

Unlike other presentations on this topic, patients will share their C. diff. infection journeys, providing a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials and studies, C diff. in pediatric patients and more.

All presentations will be designed for the lay person to easily understand and attendees will be able to ask questions directly to the keynote speakers via a live chat feature after each presentation.

"The live chat feature is one we're excited about and believe the attendees will embrace to have their questions answered by the keynote speakers," Nancy Caralla, C Diff Foundation founding president and executive director, says.

To register for this global event, visit: https://cdifffoundation.org/patientfamilyevent/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission educating and advocating for C. diff. infection (CDI) prevention, treatments, clinical trials, environmental safety and support. Its mission continues to move forward and grow through research conducted by government, industry and academia strengthening the advocacy on behalf of patients, healthcare professionals and researchers, worldwide.

For more information: https://cdifffoundation.org/

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

The Seres Therapeutics organization reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0113s2p-cdiff-symposium-300dpi.jpg

Caption: Register for the Patient and Family C Diff Foundation Symposium

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities

The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely

TAMPA, Fla. -- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Most Clinical trial sites have implemented protocols to disinfect, clean and maintain environmental safety for all visitors. Telehealth is also being utilized between healthcare professionals and patients who choose to participate in clinical trials.

C. diff. continues to be a leading cause of infectious disease deaths and in the U.S., nearly half a million Americans suffer from it, according to the CDC. It's important for patients to know that research is still happening to combat this infectious disease.

Even during these unprecedented times, clinical trials continue to press onward to resolve CDI's. The C Diff Foundation's mission in educating and advocating for Clostridioides difficile awareness, prevention, treatments, diagnostics, clinical trials, and environmental safety, forges ahead utilizing live, and pre-recorded media to reach health care professionals, patients, families, and caregivers worldwide.

For more information, call the C Diff Foundation at: 727-205-3922, or email: info@cdifffoundation.com.

C Diff Foundation: https://cdifffoundation.org/.

Clinical trial information: https://clinicaltrials.gov/ and https://cdiffclinicaltrials.com/

About ClinicalTrials.gov

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C. difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0111s2p-cdiff-clinical-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities, Product Launches

Leading Healthcare-Associated Infection Clostridioides difficile Symposium Focuses on Patients, Families, and Caregivers

TAMPA, Fla. -- C Diff Foundation announced today that the Inaugural Patient, Family, and Caregiver C. diff. Live Virtual Symposium will be hosted on November 23, 2020 at 1 p.m.-4 p.m. EST with keynote topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. The event is complimentary with online registration http://www.cdifffoundation.org/

Presenters will deliver data and discuss critical information for an audience of individuals diagnosed and recovering from a C. difficile infection. The symposium was developed to increase awareness, expand the knowledge, and elevate advocacy skills through presentations focused on a leading Healthcare-Associated Infection (HAI) Clostridioides difficile Prevention, Treatments, Clinical Trials, Diagnostics, and Environmental Safety for Adults and Children.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the Sponsor of the Patient and Family Symposium and for partnering with the C Diff Foundation raising C. diff. awareness.

Seres Therapeutics partners with the C Diff Foundation to support this important event focused on the patients and their families who are so deeply affected by this devastating infection.

The C diff Foundation's Founding President, Executive Director, Nancy C. Caralla, a three-time C. diff. Survivor, devotes countless hours day in and day out with the members of the C Diff Foundation. As a global resource, the members of the C Diff Foundation are doing all that they can to support the educational needs of patients worldwide. It is through episodes on C. diff. Spores and More live broadcasts, the annual Symposium, and Conference that give a voice to the patients who have suffered through multiple recurrences by including these speakers in the section of the program entitled "Survivor's Journey." Only through the patient's eyes can we begin to truly understand their experiences, and the unmet needs.

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics:

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, Microbiome, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook

Twitter @cdiffFoundation #Cdiffpatientsfamily2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/20-1119s2p-cdiff-symposium-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities

2020 International Clostridioides difficile (C. diff., C. difficile) Virtual Conference and Health EXPO Nov. 14

TAMPA, Fla. -- C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile, Gut Microbiome, Infection Prevention, and global healthcare-associated issues on November 14, 2020 with a live online program under the direction of IT professionals at WhiteHat Communications.

To learn more about this extraordinary conference, guest speakers, poster presentations, and the diverse topics being presented visit: https://cdiff2020.com/guest-speakers-1

All attendees will have the highest levels of online networking and learning opportunity at the Conference and Health EXPO and registration is complimentary this year. Save the date: November 4th and 5th, 2021 the 9th Annual conference will be hosted at the Boston Logan Hilton Hotel in Boston, Mass.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by a medical educational Grant from Pfizer and the members of the C Diff Foundation are profoundly grateful.

Attendee Paul Feuerstadt, MD, FACG, AGAF stated "The level of detail and data presented has a wonderful balance for those with an interest in the scientific research and interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

"I am excited to virtually meet and interact with everyone for the online extraordinaire C difficile foundation 2020 meeting. We will discuss all things C difficile and remember to tune in for my talk on the excitement of microbiome therapeutics for recurrent C difficile," stated Sahil Khanna, M.B.B.S., M.S.

The scientific data will be delivered through live virtual presentations and poster presentations at the 8th Annual International C. diff. Virtual Conference and Health Expo https://cdiff2020.com which coincides with the proclaimed; "November is Clostridioides difficile (C. diff., C. difficile) Awareness Month."

Scott Battles, VP of the C Diff Foundation stated, "We are profoundly grateful to the United States Governors for supporting our mission, along with our domestic and international partners."

November 18 - 24, 2020 Be Antibiotics Aware, a CDC educational effort, complements U.S. Antibiotic Awareness Week by providing partners with up-to-date information to help improve human antibiotic prescribing and use in the United States.

"None of us can do this alone, all of us can do this together."

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Download "C diff and You" app from Apple and Google Stores.

Twitter @cdiffFoundation #Cdiff2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

IMAGE LINKS FOR MEDIA:

[1] https://www.Send2Press.com/300dpi/30-1111s2p-cdiff8th-splash-300dpi.jpg

[2] https://www.Send2Press.com/300dpi/20-1111s2p-Cdiff640-920Conf-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.